drugset / Trial / NCT02269852

The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

NCT02269852

Phase 4 Completed 182 enrolled Sinovac Biotech Co., Ltd
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy seniors aged \> 60 years.

Timeline

Start
2013-12
Primary completion
2014-04
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anflu Vaccine 0.25 ml
Subject Anflu Vaccine 0.5 ml

Indications